Affordable Access

deepdyve-link
Publisher Website

Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center

Authors
  • Kong, Lin1, 2
  • Wu, Jinsong3
  • Gao, Jing2, 4
  • Qiu, Xianxin2, 4
  • Yang, Jing2, 4
  • Hu, Jiyi2, 4
  • Hu, Weixu2, 4
  • Mao, Ying3
  • Lu, Jiade J.2, 4
  • 1 Fudan University Shanghai Cancer Center, China , (China)
  • 2 Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, China , (China)
  • 3 Fudan University Shanghai Huashan Hospital, China , (China)
  • 4 Shanghai Proton and Heavy Ion Center, China , (China)
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Mar 13, 2020
Volume
126
Issue
12
Pages
2802–2810
Identifiers
DOI: 10.1002/cncr.32828
PMID: 32167589
PMCID: PMC7317504
Source
PubMed Central
Keywords
License
Unknown
External links

Abstract

Particle radiotherapy with concurrent temozolomide could potentially produce better outcomes than conventional radiotherapy plus temozolomide. Particle radiotherapy to a dose of ≥60 gray‐equivalents with concurrent temozolomide is safe for patients with high‐grade glioma.

Report this publication

Statistics

Seen <100 times